Rochelle Thompson, CRNA | |
41 Parsons Way, Avon, CT 06001-2545 | |
(718) 506-2076 | |
Not Available |
Full Name | Rochelle Thompson |
---|---|
Gender | Female |
Speciality | Nurse Anesthetist, Certified Registered |
Location | 41 Parsons Way, Avon, Connecticut |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811660137 | NPI | - | NPPES |
Entity Name | Resource Anesthesiology Associates Of Ct Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1447233176 PECOS PAC ID: 7517991052 Enrollment ID: O20050923000140 |
News Archive
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.
Neuroscientists at Mayo Clinic in Florida and at Aarhus University in Denmark have shed light on why neurons in the brain's reward system can be miswired, potentially contributing to disorders such as attention deficit hyperactivity disorder (ADHD).
Rodman & Renshaw Capital Group, Inc. announced today that its affiliate, Aceras BioMedical LLC (Aceras), has sold Huxley Pharmaceuticals Inc. (Huxley), a portfolio company, to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Huxley was established by Aceras in August 2008 with a focus on developing therapeutic products for rare diseases of the nervous system.
Epeius Biotechnologies Corporation today announces the clinical results of the study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Rochelle Thompson, CRNA 41 Parsons Way, Avon, CT 06001-2545 Ph: (718) 506-2076 | Rochelle Thompson, CRNA 41 Parsons Way, Avon, CT 06001-2545 Ph: (718) 506-2076 |
News Archive
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.
Neuroscientists at Mayo Clinic in Florida and at Aarhus University in Denmark have shed light on why neurons in the brain's reward system can be miswired, potentially contributing to disorders such as attention deficit hyperactivity disorder (ADHD).
Rodman & Renshaw Capital Group, Inc. announced today that its affiliate, Aceras BioMedical LLC (Aceras), has sold Huxley Pharmaceuticals Inc. (Huxley), a portfolio company, to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Huxley was established by Aceras in August 2008 with a focus on developing therapeutic products for rare diseases of the nervous system.
Epeius Biotechnologies Corporation today announces the clinical results of the study entitled "A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol" at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.
› Verified 8 days ago